Skip to main content

Table 2 Detailed information on each patient

From: Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study

Patient Gleason score PSA (ng/ml) Roach formula risk (%) Primary staging (CT = 1, MRI = 2, Choline-PET = 3) cTNM without PSMA-PET cTNM including PSMA-PET
      T N M T N M
1 6 19.1 13 1, 2, 3 1c 1 0 1c 0 0
2 7 8.5 16 1,2 3a 0 0 3b 0 0
3 8 9.6 26 1,2 2c X 0 2c 1 0
4 6 39.6 26 1,2 3b 0 0 3b 1 0
5 9 34.2 53 1 1c 0 0 2b 0 0
6 6 8.2 6 1,2 2c 0 0 2c 0 0
7 7 36 34 1,2 3a 0 0 3a 1 1 a
8 6 10.8 7 1 1c 0 0 2a 0 0
9 7 23 25 1,2 3b 0 0 3b 0 0
10 8 9.4 26 1,2,3 2c 1 0 2c 0 0
11 8 13.5 29 1 2b 0 0 3b 0 0
12 7 8.7 16 1,2 1c 0 0 2a 0 0
13 6 63.9 43 1 1c 0 0 2c 0 0
14 9 9.6 36 1,2 1c 0 0 2c 0 0
15 8 23 35 1, 2 1c X X 2c 1 Xb
  1. Shown are biopsy Gleason score, maximum PSA level before treatment and calculation of lymph node involvement following the Roach formula, as well as evolvement of tumor stages before and after PSMA-PET imaging (changes are in bold). aM1 based on para-aortal lymph nodes. bPSMA uptake in the 5th rib right, without CT morphologic correlation, suggesting possible bone metastasis